Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biocept, Inc.
  6. News
  7. Summary
    BIOC   US09072V5012

BIOCEPT, INC.

(BIOC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biocept Launches Combined COVID-19, Influenza Test; COVID-19 Test Developed With Aegea Delayed

11/22/2021 | 02:48pm EST


© MT Newswires 2021
All news about BIOCEPT, INC.
01/21Biocept Says RT-PCR Testing Volume for Coronavirus Increased This Year Amid Omicron Sur..
MT
01/21Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicro..
BU
01/04Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
BU
2021BIOCEPT : Corporate Presentation - December 2021
PU
2021Biocept's CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Pati..
BU
2021Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in..
CI
2021BIOCEPT INC : Other Events (form 8-K)
AQ
2021Aegea Says New COVID-19 Test Validated by Biocept; In Talks with FDA About Path Forward
MT
2021Biocept Launches Combined COVID-19, Influenza Test; COVID-19 Test Developed With Aegea ..
MT
2021Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Fl..
BU
More news
Analyst Recommendations on BIOCEPT, INC.
More recommendations
Financials (USD)
Sales 2021 58,4 M - -
Net income 2021 -1,70 M - -
Net Debt 2021 - - -
P/E ratio 2021 -25,2x
Yield 2021 -
Capitalization 50,9 M 50,9 M -
Capi. / Sales 2021 0,87x
Capi. / Sales 2022 1,53x
Nbr of Employees 107
Free-Float 100,0%
Chart BIOCEPT, INC.
Duration : Period :
Biocept, Inc. Technical Analysis Chart | BIOC | US09072V5012 | MarketScreener
Technical analysis trends BIOCEPT, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,02 $
Average target price 13,00 $
Spread / Average Target 330%
EPS Revisions
Managers and Directors
Michael W. Nall President, Chief Executive Officer & Director
Timothy C. Kennedy CFO, Senior VP-Operations & Secretary
Samuel D. Riccitelli Chairman
Lyle J. Arnold Chief Scientific Officer & Senior Vice President
Michael C. Dugan Chief Medical Officer & Medical Director
Sector and Competitors
1st jan.Capi. (M$)
BIOCEPT, INC.-16.57%51
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.5.89%22 461
BIOMÉRIEUX-18.57%13 650
10X GENOMICS, INC.-40.06%9 974
DIASORIN S.P.A.-14.69%8 865
NATERA, INC.-32.82%5 935